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Summary 
 
Osteoarthritis (OA) is a multifactorial, painful and disabling disease that affects millions of 
people globally, with a largely unknown aetiology. OA remains undiagnosed until it becomes 
symptomatic with advanced structural alterations evident, thus joint replacement may be 
required. OA is now considered a whole-joint inflammatory disease, associated with 
synovitis of the fibroblast-like synoviocytes (FLS). FLS are sentinel cells that contribute to 
OA pathogenesis, through secretion of various catabolic and pro-inflammatory mediators, 
though the downstream stimuli which initiate and propagate the inflammatory pathway 
remain poorly defined. Activation of the innate immune Toll-Like Receptors (TLRs) leads to 
the induction of inflammatory mediators and cellular infiltration seen in most of the joint 
arthropathies, though the role of TLRs in OA is poorly understood. The aim of this research 
work was to characterise the role and functionality of TLRs in OA and to identify the key 
TLRs that modulate OA pathology. Interestingly, we found that TLR3, activated by dsRNA 
and endogenous alarm signals contained in the OA synovial fluid (SF), plays a key role in 
OA and this was confirmed by neutralisation of TLR3 expression which shifted the balance 
from pro-inflammatory to an anti-inflammatory cytokine milieu. Next using a proteomic 
approach, we found that prohibitin 1 (PHB1), an anti-proliferative molecule, was drastically 
down-regulated in FLS upon Poly(I:C) stimulation and this was validated through confocal 
and immunoblot analysis. Thus, PHB1 may be considered as a potential biomarker for tracing 
RNA borne synovial hyperplasia, indicative of synovitis which directly implies for OA 
severity and progression. Following proteomic analysis of grade-specific whole synovial 
tissue, suppression of key complement C3b in grade-2 OA, was evident. Furthermore, grade-
specific OA-SF showed an ability to predominantly induce IFNβ in FLS and in HEK293-
TLR3 cells in a TLR3 dependent manner. Neutralisation of TLR3 significantly inhibited 
IFNβ production, probably through regulation/blockade of downstream signalling cascades of 
OA-SF-induced persistent TLR3 activation. Further, luciferase reporter gene assays have 
suggested that, this effect may be mediated through the transcription factors IRF3 and IRF9, 
leading to sustained activation of IFNβ genes. Therefore, TLR3 blockade in FLS may inhibit 
OA-SF-induced activation of TLR3 and concomitant induction of IFNβ. Likewise, TLR3 
blockade also inhibited RANTES production, primarily through blocking of NF-κB. 
Together, these data indicate that TLR3, expressed on the plasma membrane of FLS, may be 
a critical target for OA disease intervention. In conclusion, our data suggests, for the first 
time that, TLR3 hyper-activation plays a key role in perpetuating synovial inflammation in 
OA and suggests that therapeutic intervention of OA may be achieved through TLR3 
blockade. Despite the significant advances in the understanding and management of OA, 
significant research must still be undertaken before clinicians can guarantee a quality of life 
for OA patients, which is free of the debilitating pain. We hope that our efforts would, at least 
in part, contribute to a better understanding of the pathogenic molecular mechanisms that 
drive this chronic inflammatory disease. The provision of better treatments will thereby 
improve the quality of life for patients whose lives are marred by OA and related 
inflammatory diseases. 
 
